TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01869491
Drug: Compound Sodium Alginate Double Action Chewable Tablets
Normalized name: Sodium Alginate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets four times daily
Study: NCT02156739
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02156739
Drug: Gadoxetate Disodium
Normalized name: Gadoxetate Disodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01110499
Drug: AGN-210961 Formulation 4
Normalized name: AGN-201904
DrugBank: AGN-201904 (DB13135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210961 Formulation 4 in one eye once daily for 7 days.
Study: NCT03958565
Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Normalized name: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given Q12 weeks for bone disease as standard of care
Study: NCT01110499
Drug: bimatoprost ophthalmic solution 0.03%
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
Study: NCT01337687
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
Study: NCT01224756
Drug: Tinoridine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Tinoridine (DB13001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
Study: NCT03405337
Drug: Conventional FVIII replacement therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
Study: NCT02193698
Drug: Lenalidomide+Dexamethasone
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
Study: NCT01440478
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01440478
Drug: Ammonium chloride
Normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01440478
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00852956
Drug: Betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
Study: NCT02803762
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
Study: NCT04076527
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine data is collected for UDCA therapy.
Study: NCT04076527
Drug: Ocaliva
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine data is collected for OCA therapy.
Study: NCT02393586
Drug: Faropenem
Normalized name: Faropenem
DrugBank: Faropenem (DB12190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02393586
Drug: Amoxicillin/clavulanic acid 500mg/125mg
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02393586
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT00285415
Drug: Docetaxel and Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
Study: NCT04023110
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually dosed carvedilol
Study: NCT04085341
Drug: GB-102
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of GB-102
Study: NCT01033656
Drug: anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg subcutaneous injection daily
Study: NCT01326078
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 - 4 mg/kg IV, adjustment dose if necessary
Study: NCT02879747
Drug: Genotropin
Normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
Study: NCT03208933
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
Study: NCT02684487
Drug: vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
Study: NCT00845754
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg IV every 6hrs for 4 doses
Study: NCT03066154
Drug: oral docetaxel (ModraDoc/r)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly once- or twice daily ModraDoc/r
Study: NCT00154726
Drug: Paclitaxel-HDFL
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03604354
Drug: Tapentadol 100 MG Oral Tablet
Normalized name: tapentadol 100 MG Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
Study: NCT03604354
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
Study: NCT04164082
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravesically
Study: NCT03300531
Drug: Ultrasound-guided Compound betamethasone injection
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
Study: NCT02636842
Drug: Aripiprazole Lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular (IM) injection, single dose
Study: NCT00781508
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
Study: NCT04176887
Drug: Levetiracetam Injection
Normalized name: levetiracetam Injection
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
Study: NCT02917993
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
Study: NCT02917993
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 80 mg once daily (QD)
Study: NCT00006367
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006367
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006367
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03988413
Drug: 25mg
Normalized name: ZINC 25MG TAB
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SYHA1402 25mg or Placebo 25mg
Study: NCT03988413
Drug: 50mg
Normalized name: ZINC 50MG TAB
DrugBank: Copper gluconate (DB11246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 50mg or Placebo 50mg
Study: NCT03580239
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Study: NCT03154333
Drug: diacerein 1% ointment
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein 1% ointment administered topically
Study: NCT02279576
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800mg/day continuously administered.
Study: NCT02279576
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
Study: NCT00124176
Drug: Racemic albuterol (R+S albuterol)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/hr continuous racemic albuterol
Study: NCT00124176
Drug: Levalbuterol (R albuterol)
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/hr continuous nebulized levalbuterol
Study: NCT00407043
Drug: Lotemax
Normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00407043
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00677924
Drug: Zalutumumab
Normalized name: Zalutumumab
DrugBank: Zalutumumab (DB12202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT03769181
Drug: isatuximab SAR650984
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03769181
Drug: cemiplimab REGN2810
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03988413
Drug: 100mg
Normalized name: NIACIN 100MG TAB
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 100mg or Placebo 100mg
Study: NCT03988413
Drug: 200mg
Normalized name: DANAZOL 200MG CAP
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SYHA1402 200mg or Placebo 200mg
Study: NCT03988413
Drug: 800mg
Normalized name: IBU 800mg Tablet
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SYHA1402 800mg or Placebo 800mg
Study: NCT04378010
Drug: EDP-305 2 mg
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03601000
Drug: Yi-Zhi-An-Shen
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
Study: NCT03149393
Drug: Mosapride Citrate Tablets
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
Study: NCT01792284
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
Study: NCT00284076
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02663687
Drug: Recombinant human C1 esterase inhibitor
Normalized name: Recombinant human C1-esterase inhibitor
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subjects will receive escalating doses I-IV as both IV and SC injections
Study: NCT02492581
Drug: Nalmefene
Normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
Study: NCT00794495
Drug: Desloratadine 5 mg (Clarinex)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarinex 5 mg daily x 7 days
Study: NCT04394182
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100/400 mg/12h; 7-10 days
Study: NCT04394182
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/12h
Study: NCT04394182
Drug: Piperacillin/tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
Study: NCT04394182
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600mg single dose
Study: NCT00112697
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00112697
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01395862
Drug: Salmeterol and Fluticasone
Normalized name: salmeterol and fluticasone
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03882008
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
Study: NCT00276081
Drug: Gabapentin, Estrogen and placebo administration
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03156361
Drug: HDV insulin lispro 100 UNIT/mL
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
Study: NCT00794495
Drug: Cetirizine (Zyrtec)
Normalized name: cetirizine Oral Solution [Zyrtec]
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zyrtec 10 mg daily x 7 days
Study: NCT03156361
Drug: Insulin Lispro 100 Units/mL
Normalized name: insulin lispro 100 units/mL injectable solution
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sterile Water for Injection added to commercial insulin lispro
Study: NCT00246688
Drug: Sagopilone (BAY86-5302 , ZK219477)
Normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 mg lyophilized sagopilone per vial
Study: NCT01880047
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
Study: NCT00417482
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
Study: NCT03767036
Drug: Tramadol hydrochloride 25 mg capsule
Normalized name: tramadol hydrochloride 25 MG
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
Study: NCT01593722
Drug: Diethylcarbamazine
Normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT01593722
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT03767036
Drug: Ketorolac Tromethamine 10 mg tablet
Normalized name: Ketorolac tromethamine 10 mg tablet for oral suspension
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
Study: NCT01411930
Drug: Intramuscular olanzapine, aripiprazole
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole
Study: NCT01411930
Drug: Intramuscular aripiprazole, olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine
Study: NCT02793193
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Xifaxan ® will be 200mg per tablet
Study: NCT02513459
Drug: Risankizumab 600 mg IV
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
Study: NCT02513459
Drug: Risankizumab 180 mg SC
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Study: NCT00330200
Drug: ISIS 113715
Normalized name: ISIS 113715
DrugBank: ISIS 113715 (DB05506)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00379587
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab at months 3, 6, 9 and 12 post-transplant
Study: NCT00379587
Drug: 375 mg/m2 RRituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 q3months
Study: NCT02600806
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
Study: NCT01226147
Drug: Tamibarotene
Normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 4mg/day for 24 weeks.
Study: NCT04361331
Drug: Lenvatinib combined with gemox
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm2: Lenvatinib + gemox
Study: NCT04361331
Drug: Toripalimab combined with lenvatinib
Normalized name: Toripalimab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Toripalimab combined with lenvatinib
Study: NCT01169649
Drug: MK-2206
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
Study: NCT03656926
Drug: Liposomal Cyclosporine A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study: NCT00923195
Drug: Montanide ISA 51 VG
Normalized name: Montanide ISA 51 VG
DrugBank: Incomplete Freund's adjuvant (DB17475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.